Anonymous
Guest
Anonymous
Guest
So is anyone else concerned with our division? The budget has not been announced, with have a large number of vacancies across the nation, the DOJ decision still has not been announced and our VP just left. Let's put this in perspective, we have ONE product we promote with declining sales. Most territories across the nation generate less than a million in revenue and yet our target comps ae $150K. Reps in other true device positions (J&J, BARD, Boston Sci, etc) have similar comps but typically generate several million in revenue for their territories. If I am Sanofi corporate, I would be looking at our division as just one big headache. Anyone else have any thoughts?